Extracellular Vesicles as Therapeutic and Diagnostic Tools for Chronic Liver Diseases.
Extracellular Vesicles as Therapeutic and Diagnostic Tools for Chronic Liver Diseases.
复制标题
DOI：
10.3390/biomedicines11102808
复制
发表时间：
2023-10-17
期刊：
影响因子：
4.7
通讯作者：
中科院分区：
文献类型：
--
作者：
慢性肝脏疾病可导致纤维化变化，可能发展为肝硬化，这对发病率和死亡率增加构成重大风险。代谢功能障碍相关性脂肪性肝病（MASLD）、酒精相关性肝病（ALD）和病毒性肝炎是可能导致肝硬化的常见肝病。肝硬化的晚期阶段可以进一步复杂化癌症发展或终末期肝病和肝功能衰竭。因此，肝纤维化的早期检测和诊断对于防止进展为肝硬化和改善患者预后至关重要。传统上，侵入性肝活检被认为是诊断和分期肝纤维化的金标准。在过去的十年中，研究集中在非侵入性方法上，称为液体活检，其涉及识别人体液体（如血液）中的疾病特异性生物标志物。在这些替代方法中，细胞外囊泡（EV）已成为各种疾病（包括慢性肝病）的有前景的诊断和治疗工具。EV从应激或受损的细胞中释放出来，可以分离和定量。此外，EV通过运输各种货物来促进细胞与细胞之间的通信，并且它们已经显示出减少促纤维化标记物表达的潜力，使它们成为新型抗纤维化治疗的有吸引力的工具。本文综述了EV在慢性肝病中的影响，并探讨了其在创新治疗和诊断方法中的潜在应用。
Chronic liver diseases can lead to fibrotic changes that may progress to the development of cirrhosis, which poses a significant risk for morbidity and increased mortality rates. Metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-associated liver disease (ALD), and viral hepatitis are prevalent liver diseases that may lead to cirrhosis. The advanced stages of cirrhosis can be further complicated by cancer development or end-stage liver disease and liver failure. Hence, early detection and diagnosis of liver fibrosis is crucial for preventing the progression to cirrhosis and improving patient outcomes. Traditionally, invasive liver biopsy has been considered the gold standard for diagnosing and staging liver fibrosis. In the last decade, research has focused on non-invasive methods, known as liquid biopsies, which involve the identification of disease-specific biomarkers in human fluids, such as blood. Among these alternative approaches, extracellular vesicles (EVs) have emerged as promising diagnostic and therapeutic tools for various diseases, including chronic liver diseases. EVs are released from stressed or damaged cells and can be isolated and quantified. Moreover, EVs facilitate cell-to-cell communication by transporting various cargo, and they have shown the potential to reduce the expression of profibrogenic markers, making them appealing tools for novel anti-fibrotic treatments. This review focuses on the impact of EVs in chronic liver diseases and exploring their potential applications in innovative therapeutic and diagnostic approaches.
登录
查看更多内容
DOI：
10.1007/s00109-020-01926-7
发表时间：
2020-07
期刊：
Journal of molecular medicine (Berlin, Germany)
影响因子：
--
作者：
Eguchi A;Yan R;Pan SQ;Wu R;Kim J;Chen Y;Ansong C;Smith RD;Tempaku M;Ohno-Machado L;Takei Y;Feldstein AE;Tsukamoto H
通讯作者：
Tsukamoto H
人脐带 MSC 衍生的外泌体通过抗氧化作用抑制 CCl4 诱导的肝损伤的发展
影响因子：
4.3
作者：
Jiang W;Tan Y;Cai M;Zhao T;Mao F;Zhang X;Xu W;Yan Z;Qian H;Yan Y
通讯作者：
Yan Y
DOI：
10.1038/s41580-023-00585-z
发表时间：
2023-08
期刊：
Nature reviews. Molecular cell biology
影响因子：
--
作者：
通讯作者：
--
影响因子：
8.8
作者：
Hishida, Tomoaki;Yamamoto, Mako;Hishida-Nozaki, Yuriko;Shao, Changwei;Huang, Ling;Wang, Chao;Shojima, Kensaku;Xue, Yuan;Hang, Yuqing;Shokhirev, Maxim;Memczak, Sebastian;Sahu, Sanjeeb Kumar;Hatanaka, Fumiyuki;Ros, Ruben Rabadan;Maxwell, Matthew B.;Chavez, Jasmine;Shao, Yanjiao;Liao, Hsin-Kai;Martinez-Redondo, Paloma;Guillen-Guillen, Isabel;Hernandez-Benitez, Reyna;Esteban, Concepcion Rodriguez;Qu, Jing;Holmes, Michael C.;Yi, Fei;Hickey, Raymond D.;Guillen Garcia, Pedro;Nunez Delicado, Estrella;Castells, Antoni;Campistol, Josep M.;Yu, Yang;Hargreaves, Diana C.;Asai, Akihiro;Reddy, Pradeep;Liu, Guang-Hui;Belmonte, Juan Carlos Izpisua
通讯作者：
Belmonte, Juan Carlos Izpisua
酒精性肝病：发病机制和新的治疗靶点。
影响因子：
29.4
作者：
Gao B;Bataller R
通讯作者：
Bataller R